Lilly drug helps patients live longer in lung cancer study, skeptics await full data
This article was originally published in Scrip
Executive Summary
Eli Lilly said its experimental drug necitumumab met a goal of helping previously untreated lung cancer patients live longer in a late-stage study, an unexpected development that boosted the company’s stock price.